HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Bayer bonds, Nestle investment, P&G and Abbott earnings, NAD reviews

This article was originally published in The Tan Sheet

Executive Summary

Bayer targets acquisitions with bond proceeds; Nestle commits $1 bil. to Mexico expansion; P&G health care sales grow 4%; U.S. sales slow Abbott Nutrition; NAD refers Grey Defence to FTC; Rainbow Light pulls anti-aging claims; and medical food warning letter.

You may also be interested in...



Major OTC Acquisitions, Expansion Likely In 2014

With major consumer product divisions potentially in play, analysts take a look at possible buyers and sellers in the OTC space. Switches and consumer business expansion plans are also likely to shape 2014.

Stock Watch: Beware The Halo Effect Of Biopharma Leaders

Some entrepreneurs combine talent and experience to produce multiple profitable exits for investors. But there are many who do not, and past success is indeed no guarantee of future performance.

OTC Marketing Awards 2022: What The Judges Said About The Leading Entries

The trophies have been handed out at the OTC Marketing Awards 2022 - but what did the expert judges have to say about the winning and highly-commended entries?

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS139472

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel